Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 83, Issue 4, Pages 1130-1143Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2020.04.105
Keywords
adverse event; atezolizumab; avelumab; bullous pemphigoid; checkpoint inhibitor; CTLA-4; cutaneous; durvalumab; immunotherapy; ipilimumab; lichenoid dermatitis; nivolumab; PD1; PD-L1; pembrolizumab; rash; skin; toxicity
Categories
Funding
- Dermatology Foundation, through Dermatopathology Career Development Award
- National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health [K23AR074530, U01AR077511]
- Berg
- Lutris
- Paxman
- Novocure
- US Biotest
- Veloce
- National Institutes of Health/National Cancer Institute Cancer Center Support Grant [P30-CA0-08748]
Ask authors/readers for more resources
Antineoplastic agents that use the immune system have revolutionized cancer treatment. Specifically, implementation of immune checkpoint inhibitors, monoclonal antibodies that block cytotoxic T-lymphocyte-associated antigen-4, programmed cell death protein 1, or programmed cell death ligand 1 show improved and sustained responses in patients with cancer. However, these agents are associated with a plethora of adverse events, many manifesting in the skin. As the clinical application of cancer immunotherapies expands, understanding the clinical and histopathologic features of associated cutaneous toxicities becomes increasingly important to dermatologists, oncologists, and pathologists to ensure timely diagnosis and appropriate care. This review discusses cutaneous reactions to immune checkpoint inhibitors, focusing on histopathologic features.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available